Akkerman-Nijland, A.M.; Hagedoorn, P.; Rottier, B.L.; Grasmeijer, F.; Frijlink, H.W.; van Luin, M.; ter Weijden, E.; Merkus, P.J.; Touw, D.J.; Akkerman, O.W.;
et al. Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis. Pharmaceutics 2025, 17, 347.
https://doi.org/10.3390/pharmaceutics17030347
AMA Style
Akkerman-Nijland AM, Hagedoorn P, Rottier BL, Grasmeijer F, Frijlink HW, van Luin M, ter Weijden E, Merkus PJ, Touw DJ, Akkerman OW,
et al. Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis. Pharmaceutics. 2025; 17(3):347.
https://doi.org/10.3390/pharmaceutics17030347
Chicago/Turabian Style
Akkerman-Nijland, Anne M., Paul Hagedoorn, Bart L. Rottier, Floris Grasmeijer, Henderik (Erik) W. Frijlink, Mathijs van Luin, E. ter Weijden, Peter J. Merkus, Daan J. Touw, Onno W. Akkerman,
and et al. 2025. "Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis" Pharmaceutics 17, no. 3: 347.
https://doi.org/10.3390/pharmaceutics17030347
APA Style
Akkerman-Nijland, A. M., Hagedoorn, P., Rottier, B. L., Grasmeijer, F., Frijlink, H. W., van Luin, M., ter Weijden, E., Merkus, P. J., Touw, D. J., Akkerman, O. W., & Koppelman, G. H.
(2025). Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis. Pharmaceutics, 17(3), 347.
https://doi.org/10.3390/pharmaceutics17030347
